Chardan Capital Markets
http://www.chardancm.comChardan Capital Markets is an international investment bank headquartered in New York City, with offices in Los Angeles and Beijing. Chardan provides a wide array of financial services including investment banking, capital markets, international trading and equity research. The investment banking group focuses on providing banking and advisory services to private and public companies in small and mid-cap markets. The institutional coverage of Chardan Capital Markets spans North America, Europe and Asia. Chardan Capital Markets LLC is a registered broker-dealer with the U.S. Securities and Exchange Commission and is a member of the following: Financial Industry Regulatory Authority (FINRA); Municipal Securities Rulemaking Board (MSRB); Securities Insurance Protection Corporation (SIPC); NASDAQ Stock Market and the NYSE Arca, Inc.
View Older Stories View More Recent Stories
-
HUDSON CAPITAL INC. ANNOUNCES $1.6 MILLION REGISTERED DIRECT OFFERING
-
HUDSON CAPITAL INC. ANNOUNCES $1.6 MILLION REGISTERED DIRECT OFFERING
-
Should You Buy Penny Stocks? Here's What Analysts Think
-
PTK Acquisition Corp. Announces Closing of $115 Million Initial Public Offering
-
Moderna (MRNA) PT Raised to $95 at Chardan Capital Markets
-
PTK Acquisition Corp. (PTK) Prices 10M Unit IPO at $10/Unit
-
PTK Acquisition Corp. Announces Pricing of $100 Million Initial Public Offering
-
Ucommune and Orisun Acquisition Corp. Combine to Bring to the Public Markets the Most Recognized and Largest Agile Office Space Manager and Co-Working Community Operator in China
-
Immatics Announces Completion of Business Combination and Listing on NASDAQ
-
Immatics Announces Completion of Business Combination and Listing on NASDAQ
-
Chardan Capital Markets Downgrades OncoCyte Corp (OCX) to Neutral
-
Arya Sciences Acquisition Corp. (ARYA) Shareholders Approve Business Combination Transaction with Immatics
-
Arya Sciences Acquisition Corp. Shareholders Approve Business Combination Transaction with Immatics
-
Mountain Crest Acquisition Corp Announces Closing of Over-Allotment Option in Connection With Its Initial Public Offering
-
Hudson Capital (HUSN) enters agreements with investors for purchase and sale of 4.35M ordinary shares at $0.85 per share
-
HUDSON CAPITAL INC. ANNOUNCES $3.7 MILLION REGISTERED DIRECT OFFERING
-
HUDSON CAPITAL INC. ANNOUNCES $3.7 MILLION REGISTERED DIRECT OFFERING
-
Sensorion Announces Initiation of Coverage by US Investment Bank Chardan with a “Buy” Recommendation
-
Chardan Healthcare Acquisition 2 Corp. Securities To Commence Separate Trading
-
Axovant Gene Therapies (AXGT) PT Raised to $15 at Chardan Capital Markets
-
Form 8-K Chardan Healthcare Acqui For: Jun 05
-
Mountain Crest Acquisition Corp Announces Closing of $50 Million Initial Public Offering
-
Emergent BioSolutions (EBS) Faces Challenges as TEVA Wins Patent Dispute - Chardan
-
Chardan Capital Markets Starts Sonnet BioTherapeutics (SONN) at Buy
-
UPDATE: Chardan Capital Markets Starts ARYA Sciences Acquisition Corp. (ARYA) at Buy
-
UPDATE: Mountain Crest Acquisition Corp (MCAC) Prices 5M Unit IPO at $10/Unit
-
Mountain Crest Acquisition Corp Announces Pricing of $50 Million Initial Public Offering
-
Form 10-Q Chardan Healthcare Acqui For: Mar 31
-
Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit
-
Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit
-
UPDATE: Krystal Biotech (KRYS) Prices 2.275M Share Common Offering at $55/Sh
-
Krystal Biotech Announces Pricing of $125 Million Public Offering of Common Stock
-
Wealthbridge Acquisition Limited and Scienjoy Inc. Announce Closing of Business Combination
-
Form SC 13G Chardan Healthcare Acqui Filed by: Oliveira Steven Michael
-
UPDATE: Chardan Capital Markets Starts Madrigal Pharmaceuticals (MDGL) at Buy
-
UPDATE: Chardan Capital Markets Starts Viking Therapeutic (VKTX) at Buy
-
Form 8-K Chardan Healthcare Acqui For: Apr 28
-
Emergent BioSolutions (EBS) PT Raised to $86 at Chardan Capital Markets
-
NeuBase Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Form 8-K Chardan Healthcare Acqui For: Apr 23
-
Chardan Healthcare Acquisition 2 Corp. Announces Closing of $85 Million Initial Public Offering
-
Form 424B4 Chardan Healthcare Acqui
-
NeuBase Therapeutics (NBSE) Prices 5.25M Share Common Offering at $6/Sh
-
NeuBase Therapeutics Announces Pricing of $31,500,000 Public Offering of Common Stock
-
Moderna (MRNA) PT Raised to $52 at Chardan Capital After COVID-19 Vaccine Phase 2 IND Filed
-
Form 3 Chardan Healthcare Acqui For: Apr 23 Filed by: Session R.A. II
-
Form 3 Chardan Healthcare Acqui For: Apr 23 Filed by: Manke Isaac
-
Form EFFECT Chardan Healthcare Acqui
-
Chardan Healthcare Acquisition 2 Corp. (CHAQ) Prices 8.5M Unit IPO at $10/Unit
-
Chardan Healthcare Acquisition 2 Corp. Announces Pricing of $85 Million Initial Public Offering

